G1 Therapeutics Inc (G1H.BE)
- GlobeNewswire
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 2,800 shares of G1’s common stock and 1,400 restricted stock units (RSUs) to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”). These equity awards were granted as an inducement material to th
- GlobeNewswire
G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on January 19th, 2023, at 11:30 AM EST, G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the virtual 2023 B. Riley Securities 3rd Annual Oncology Conference. The webcast of the event will be accessible on the Events & Presentations page of http://www.g1therapeutics.com. About G1 TherapeuticsG1 Therapeu
- GlobeNewswire
G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
- Initial Results from Pivotal Phase 3 PRESERVE 1 Trial in Colorectal Cancer Expected in February 2023; Positive Results Would Initiate Regulatory Interactions for Label Expansion - - Five Clinical Trials with Data Readouts in 2023 Will Evaluate Trilaciclib On-Target Effects of Myeloprotection and Enhanced Immune Function with Potential for Improved Efficacy Outcomes (Progression Free (PFS) and Overall Survival (OS)) - - Trilaciclib’s Potential Synergistic Effects with Chemotherapy, Antibody Dru
